Lead Product(s): GEN1042
Therapeutic Area: Oncology Product Name: GEN1042
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 23, 2020
Genmab together with BioNTech, has begun clinical development of an investigational therapy, GEN1042 (DuoBody®-CD40x4-1BB), for solid tumors. GEN1042 is a novel bispecific agonistic antibody targeting CD40 and 4-1BB for priming and activation of tumor-specific immune response.